O 6-Alkylguanine-DNA Alkyltransferase in Cutaneous T-Cell Lymphoma : Implications for Treatment with Alkylating Agents 1

Mycosis fungoides is a low-grade cutaneous T-cell lymphoma. Early treatment often involves the use of topical chemotherapy such as mechlorethamine or carmustine although single-agent oral chemotherapy with alkylators is common for advanced disease. Recently, in a Phase I study of the new alkylating agent temozolomide, two mycosis fungoides patients experienced a complete response. The mechanism of resistance to alkylating drugs such as temozolomide is thought to be due to the presence in tumor cells of the DNA repair protein, O-alkylguanine-DNA alkyltransferase (AGT). The protein mediates a reaction with the O-position of guanine in DNA, removing the lesion and leaving guanine intact. We, therefore, examined the levels of AGT in CD41 T lymphocytes obtained by negative antibody selection from the blood of noncancerous individuals and mycosis fungoides patients, and in paraffin-embedded sections from mycosis fungoides patch, plaque, or tumor lesions and cells from involved lymph nodes. AGT protein levels were measured by quantitative immunofluorescence microscopy using a monoclonal antibody against human AGT. Using this approach, the mean level of our positive control (AGT-expressing cells) was 84,807 molecules/nucleus; values below 5,000 molecules/nucleus are considered very low. The mean AGT level in CD41 T lymphocytes from noncancerous and cancerous individuals was 18,618 ( n 5 12) and 8,593 (n 5 5), respectively. The mean fraction of outliers in circulating CD41 T lymphocytes from mycosis fungoides patients was statistically significantly lower than T cells in lymph nodes. AGT molecules/nucleus from lymph node biopsies from 8 of 10 patients showed low ( <10,000 molecules/ nucleus) or undetectable levels ( n 5 5) of AGT. The mean AGT level from samples of mycosis fungoides patch/plaque and tumor was also low at 221 ( n 5 4) and 2,363 ( n 5 6), respectively. Surprisingly, Hut78, a mycosis fungoides T-cell lymphoma cell line, was positive for AGT activity (median: 77,700 molecules/nucleus), and Hut102—another mycosis fungoides cell line—was low (median: 5,990 molecules/nucleus). Because AGT is a primary means of cell resistance to alkylating agents, the low level of AGT in neoplastic T lymphocytes from patients with mycosis fungoides suggests that treatment with alkylating agents producing O-alkylguanine adducts, such as carmustine or temozolomide, may produce improved clinical outcomes.

[1]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[2]  T. Brent,et al.  Methylation of selected CpGs in the human O6‐methylguanine‐DNA methyltransferase promoter region as a marker of gene silencing , 1999, Molecular carcinogenesis.

[3]  P. Goodfellow,et al.  A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers , 1999, Molecular carcinogenesis.

[4]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[5]  H. Eyre,et al.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Ramana,et al.  Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. , 1998, Cancer research.

[7]  W. Jurecka,et al.  Longterm remission of tumor-stage mycosis fungoides following total-skin electron-beam radiotherapy. , 1998, European journal of dermatology : EJD.

[8]  T. Fitzpatrick,et al.  The benefits and risks of long-term PUVA photochemotherapy. , 1998, Dermatologic clinics.

[9]  M. Berger,et al.  O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. , 1998, Cancer research.

[10]  R. Pieper,et al.  Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning , 1997, Molecular and cellular biology.

[11]  T. Brent,et al.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. , 1997, Cancer research.

[12]  L. Wilson,et al.  Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). , 1997, International journal of radiation oncology, biology, physics.

[13]  D. Cooper,et al.  Low O6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GC-->AT transition in the K-ras oncogene. , 1997, Carcinogenesis.

[14]  M. Dolan,et al.  O6-benzylguanine and its role in chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  L. Wilson,et al.  Mycosis fungoides and total skin electron beam radiation. , 1997, Blood.

[16]  A. Watson Photochemotherapy for mycosis fungoides: Current status * , 1997, The Australasian journal of dermatology.

[17]  C. Kjellström,et al.  PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread. , 1996, Acta dermato-venereologica.

[18]  M. Prados,et al.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.

[19]  D. Ramsay,et al.  Topical treatment of early cutaneous T-cell lymphoma. , 1995, Hematology/oncology clinics of North America.

[20]  S. Shaw,et al.  Immunomagnetic Purification of T Cell Subpopulations , 1995, Current protocols in immunology.

[21]  J. Willson,et al.  O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. , 1995, Hematology/oncology clinics of North America.

[22]  G. Wani,et al.  Differential expression of the o6‐alkylguanine‐DNA alkyltransferase gene in normal human breast and skin tissue: In situ mapping of cell type‐specific expression , 1995, Molecular carcinogenesis.

[23]  L. Golitz,et al.  Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome) , 1994, Annals of Internal Medicine.

[24]  H S Zackheim,et al.  Treatment of cutaneous T-cell lymphoma. , 1994, Seminars in dermatology.

[25]  H. Zackheim Topical carmustine (BCNU) for patch/plaque mycosis fungoides. , 1994, Seminars in dermatology.

[26]  M. Berger,et al.  Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. , 1993, Cancer research.

[27]  E. Newlands,et al.  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.

[28]  G. Wood,et al.  Mycosis fungoides: Clinical and histologic features, staging, evaluation, and approach to treatment , 1993, CA: a cancer journal for clinicians.

[29]  S. Culine,et al.  Overexpression of the ras-related rab2 gene product in peripheral blood mononuclear cells from patients with hematological and solid neoplasms. , 1992, Cancer research.

[30]  C. Quarterman,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[31]  A. Tosca,et al.  Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides. , 1991, Anticancer research.

[32]  T. Kuzel,et al.  Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Kuzel,et al.  Cutaneous T-cell lymphoma. , 1991, Oncology nursing forum.

[34]  D. Ludlum DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. , 1990, Mutation research.

[35]  S. Belinsky,et al.  Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. , 1989, Cancer research.

[36]  E. Sausville,et al.  Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. , 1985, Human pathology.

[37]  J. Antolak,et al.  Utilization of thermoluminescent dosimetry in total skin electron beam radiotherapy of mycosis fungoides. , 1998, International journal of radiation oncology, biology, physics.

[38]  C. Weghorst,et al.  Molecular characterization of mutations in the hprt gene of normal human skin keratinocytes treated with N‐ethyl‐N‐nitrosourea: Influence of O6‐alkylguanine alkyltransferase , 1997, Environmental and molecular mutagenesis.

[39]  D. Ludlum The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. , 1997, Cancer investigation.

[40]  J. Allay,et al.  Role of DNA repair in resistance to drugs that alkylate O6 of guanine. , 1996, Cancer treatment and research.

[41]  M. Citron,et al.  Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase , 1996, Cancer Chemotherapy and Pharmacology.

[42]  M. Dolan,et al.  Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.